Jason Kim

Jason Kim

Auto-generated profile, based on publicly available information

Jason Kim

Division of Hematology and Oncology, Department of Medicine, University of Washington, Seattle, Washington. 1

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 June 2024 in Blood Cancer Discovery
Verified
Journal Article
Open access
PDF file
MSMartina Sarchi
Martina Sarchi
CCCourtnee A. Clough
Courtnee A. Clough
ECEdie I. Crosse
Edie I. Crosse
JKJason Kim
Jason Kim
LGLaura D. Baquero Galvis
Laura D. Baquero Galvis
SDSergei Doulatov
Sergei Doulatov
Splicing factor SF3B1 mutations are frequent somatic lesions in myeloid neoplasms that transform hematopoietic stem cells (HSCs) by inducing mis-splicing of target genes. However, the molecular and functional consequences of SF3B1 mutations in human HSCs and progenitors (HSPCs) remain unclear. Here, we identify the mis-splicing program in human HSPCs as a targetable vulnerability by precise gene editing of SF3B1 K700E mutations in primary CD34+ cells. Mutant SF3B1 induced pervasive mis-splicing and reduced expression of genes regulating mitosis and genome maintenance leading to altered differentiation, delayed G2/M progression, and profound sensitivity to CHK1 inhibition (CHK1i). Mis-splicing or reduced expression of mitotic regulators BUBR1 and CDC27 delayed G2/M transit and promoted CHK1i sensitivity. Clinical CHK1i prexasertib selectively targeted SF3B1-mutant immunophenotypic HSCs and abrogated engraftment in vivo. These findings identify mis-splicing of mitotic regulators in SF3B1-mutant HSPCs as a targetable vulnerability engaged by pharmacological CHK1 inhibition. Significance: In this study, we engineer precise SF3B1 mutations in human HSPCs and identify CHK1 inhibition as a selective vulnerability promoted by mis-splicing of mitotic regulators. These findings uncover the mis-splicing program induced by mutant SF3B1 in human HSPCs and show that it can be therapeutically targeted by clinical CHK1 inhibitors.

17 June 2026
Verified
Other
Open access
MSMartina Sarchi
Martina Sarchi
CCCourtnee A. Clough
Courtnee A. Clough
ECEdie I. Crosse
Edie I. Crosse
JKJason Kim
Jason Kim
LGLaura D. Baquero Galvis
Laura D. Baquero Galvis
SDSergei Doulatov
Sergei Doulatov
Supplemental Table 1. Splicing analysis of control and SF3B1 K700E edited cord blood (CB) and peripheral blood (PB) CD34+ cells.

17 June 2026
Verified
Other
Open access
MSMartina Sarchi
Martina Sarchi
CCCourtnee A. Clough
Courtnee A. Clough
ECEdie I. Crosse
Edie I. Crosse
JKJason Kim
Jason Kim
LGLaura D. Baquero Galvis
Laura D. Baquero Galvis
SDSergei Doulatov
Sergei Doulatov
Supplemental Table 3. Drug screening of WT (Ctrl), SF3B1 K700E (S-A), SF3B1/RUNX1 (S-R), and SF3B1/STAG2 (S-S) K562 cells with the AML OncoPanel1 of 165 FDA-approved compounds.

17 June 2026
Verified
Other
Open access
MSMartina Sarchi
Martina Sarchi
CCCourtnee A. Clough
Courtnee A. Clough
ECEdie I. Crosse
Edie I. Crosse
JKJason Kim
Jason Kim
LGLaura D. Baquero Galvis
Laura D. Baquero Galvis
SDSergei Doulatov
Sergei Doulatov
Supplemental Table 2. Splicing analysis of WT and SF3B1 K700E mutant K562 cells.

3 September 2024
Verified
Other
Open access
MSMartina Sarchi
Martina Sarchi
CCCourtnee A. Clough
Courtnee A. Clough
ECEdie I. Crosse
Edie I. Crosse
JKJason Kim
Jason Kim
LGLaura D. Baquero Galvis
Laura D. Baquero Galvis
SDSergei Doulatov
Sergei Doulatov
Splicing factor SF3B1 mutations are frequent somatic lesions in myeloid neoplasms that transform hematopoietic stem cells (HSCs) by inducing mis-splicing of target genes. However, the molecular and functional consequences of SF3B1 mutations in human HSCs and progenitors (HSPCs) remain unclear. Here, we identify the mis-splicing program in human HSPCs as a targetable vulnerability by precise gene editing of SF3B1 K700E mutations in primary CD34+ cells. Mutant SF3B1 induced pervasive mis-splicing and reduced expression of genes regulating mitosis and genome maintenance leading to altered differentiation, delayed G2/M progression, and profound sensitivity to CHK1 inhibition (CHK1i). Mis-splicing or reduced expression of mitotic regulators BUBR1 and CDC27 delayed G2/M transit and promoted CHK1i sensitivity. Clinical CHK1i prexasertib selectively targeted SF3B1-mutant immunophenotypic HSCs and abrogated engraftment in vivo. These findings identify mis-splicing of mitotic regulators in SF3B1-mutant HSPCs as a targetable vulnerability engaged by pharmacological CHK1 inhibition.Significance: In this study, we engineer precise SF3B1 mutations in human HSPCs and identify CHK1 inhibition as a selective vulnerability promoted by mis-splicing of mitotic regulators. These findings uncover the mis-splicing program induced by mutant SF3B1 in human HSPCs and show that it can be therapeutically targeted by clinical CHK1 inhibitors.

3 September 2024
Verified
Other
Open access
PDF file
MSMartina Sarchi
Martina Sarchi
CCCourtnee A. Clough
Courtnee A. Clough
ECEdie I. Crosse
Edie I. Crosse
JKJason Kim
Jason Kim
LGLaura D. Baquero Galvis
Laura D. Baquero Galvis
SDSergei Doulatov
Sergei Doulatov
Supplementary Figure S1: Multiplex gene editing of SF3B1 K700E in CD34+ cells. Supplementary Figure S2: Splicing and single cell transcriptome analysis of SF3B1-mutant HSPCs. Supplementary Figure S3: Mis-splicing and expression of BUBR1 and CDC27. Supplementary Figure S4: Drug sensitivity of SF3B1-mutant cells. Supplementary Figure S5: The role of candidate mis-spliced genes in CHK1i sensitivity. Supplementary Figure S6: Prexasertib testing in CB HSPCs, MDS samples, and in vivo.